SCOPOLAMINE (scopolamine) by Teva is cholinergic antagonists [moa]. First approved in 2022.
Drug data last refreshed 20h ago
Cholinergic Antagonists
Anticholinergic
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
PET and MRI Imaging With Scopolamine at the Muscarinic M1 Receptor
TAK-071 Scopolamine-Induced Cognitive Impairment Study
A Comparative Bioavailability and Adhesion Performance Study, Comparing a New Scopolamine Transdermal Delivery System Formulation to the Currently Established Reference Transdermal Delivery System in Healthy Adult Participants.
Roflumilast and Donepezil to Reverse Scopolamine Induced Cognitive Deficits in Healthy Adults
Assessment Of The Effects Of Single Doses Of An Investigational Drug, Given Alone Or With Donepezil, On Scopolamine-Induced Changes In Memory And Learning In Healthy Adults
Worked on SCOPOLAMINE at Teva? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.